Wire · operational-macro
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
NeOnc Technologies Holdings reported encouraging Phase 2a clinical results for NEO100 in recurrent IDH1-mutant high-grade glioma, showing improved progression-free and overall survival rates. The Nasdaq listing and its $75 million ATM program position the company to leverage these results to access incremental capital for further clinical development.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Biotech founders now see Nasdaq listings as financing tools tied to clinical progress, not just stock venues. You can use positive trial results to unlock better funding terms incrementally rather than betting on pure hypothesis.
◆ Coverage
1 source · 17 Aug 2026
◆ Related on Wire
◆ Topics